ArticleWorld journal of cardiology2025
Circulating microRNAs in predicting fibrosis in hypertrophic cardiomyopathy: A systematic review.
Article in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating microRNA dysregulation in hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, and dilated cardiomyopathy: a systematic review.Systematic reviews · 2026Pooled it
- MicroRNA Signatures in Cardiometabolic Disorders as a Next-Generation Diagnostic Approach: Current Insight.International journal of molecular sciences · 2025Review
- Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy and interstitial fibrosis, which contribute to adverse outcomes such as heart failure and sudden cardiac death. While cardiac magnetic resonance (CMR) imaging is commonly used to detect myocardial fibrosis, circulating microRNAs (miRNAs) have emerged as promising noninvasive biomarkers for this condition due to their stability in blood plasma and resistance to pH and temperature variance.
aimTo explore the role of specific circulating miRNAs in identifying myocardial fibrosis in patients with HCM.
methodsUsing PubMed/MEDLINE and Google Scholar, we reviewed studies from 2014 to 2024 examining the link between circulating miRNAs and myocardial fibrosis in HCM. We included studies measuring miRNA expression in blood samples from HCM patients and assessing fibrosis
resultsSeven studies involving 365 HCM patients with a mean age of 49.37 ± 10.5 years, 116 (31.78%) females, and one animal study identified miR-21, miR-29a, miR-133, miR-4454, and miR-221 as frequently dysregulated markers associated with fibrosis. Elevated levels of miR-21 and miR-29a correlated with more extensive fibrosis, as assessed by late gadolinium enhancement in CMR imaging, with miR-29a consistently linked to both fibrosis and hypertrophy across the studies.
conclusionCirculating miRNAs, particularly miR-21, miR-29a, and miR-221, show significant potential as biomarkers for myocardial fibrosis in HCM. Further research should validate these findings and investigate the clinical application of miRNA-based diagnostics in HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.